An observational study in Complicated Urinary Tract Infection, sponsored by QIAGEN Gaithersburg, Inc. Active, not recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by QIAGEN Gaithersburg, Inc (part of QIAGEN) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Urinary Tract Infections with a site in United Kingdom — 7 open to participants now, 10 under way, none of them phase 3. Urinary Tract Infections · United Kingdom.
Among the 31 studies in Urinary Tract Infections with a site in United Kingdom, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is the only one that started in 2025, is one of 14 observational ones, and was the 28th registered.
808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.
Browse Urinary Tract Infections studies →7 of the 31 studies in Urinary Tract Infections with a site in United Kingdom are open now. Recruiting first, the newest first:
Queen's University, Belfast · Sites in United Kingdom
University College, London · Sites in United Kingdom
Ages 18+ · Women only
University of Southampton · Sites in United Kingdom
Ages 65+ · Healthy volunteers
Royal Free Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Infectopharm Arzneimittel GmbH · Sites in United Kingdom, Austria, Germany and 2 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 241 across 199 observational studies indexed under Urinary Tract Infections.
Median enrollment 48 across the 17 interventional studies, 1,250 across the 14 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under QIAGEN Gaithersburg, Inc, one of the names counted as QIAGEN. Under that name alone:
QIAGEN Gaithersburg, Inc is the lead sponsor of 27 studies on the registry; 1 is open to participants now.
QIAGEN has 1 study filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in Urinary Tract Infections with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06824129QIAGEN Gaithersburg, IncClinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR | 2026-12 |
| NCT07698041Katherine FinlayRUTISS-Diary and RUTISS-65 Study | 2027-06-30 |
| NCT06710899University Hospitals of North Midlands NHS TrustVitamin C and Hiprex in rUTI | 2027-08 |
| NCT07202949University College, LondonA Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Urinary Tract Infections with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Performance evaluation of QIAstat-Dx cUTI Plus AMR Panel using the QIAstat-Dx® Analyzer to demonstrate that the QIAstat-Dx cUTI Plus AMR Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment
The objective of the study is to demonstrate that the QIAstat-Dx cUTI Plus AMR Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment.
The primary objective is to evaluate the performance of QIAstat-Dx cUTI Plus AMR Panel in comparison with the results obtained from the reference method.
The secondary objective of the study is to evaluate the safety ofQIAstat-Dx cUTI Plus AMR Panel with respect to users/operators.
The primary study endpoint will be the results for each analyte obtained from testing prospective specimens with QIAstat-Dx cUTI Plus AMR Panel and Reference Method. Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) will be determined
Patients with signs and symptoms of complicated urine infection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Specimens from subjects of all ages and demographic characteristics can be enrolled.
Exclusion Criteria:
Specimens enrolled in the study may be excluded for the following reasons:
PPA
Positive percent agreement
Time frame: 8 months
NPA
Negative percent agreement
Time frame: 8 months
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 84 observational studies under Urinary Tract Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 53. This study's planned 12 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.